The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.

CONCLUSIONS: SGLT2 inhibitor therapy reduces CV death and hospitalizations in HFrEF patients regardless of T2DM. The decision to prescribe this class of drugs should not be determined by glycemic status.
PMID: 33401940 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - January 5, 2021 Category: Drugs & Pharmacology Authors: Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R Tags: Ann Pharmacother Source Type: research